The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type- 1 (HIV -I) and type-2 (HIV -2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. The invention is directed to a novel crystalline form of the RT inhibitor 3-chloro-5-({1-[( 4-methyl-5 -oxo-4,5 -dihydro-1H -1,2, 4-triazol-3 -yl)methyl]-2-oxo-4-( trifluoromethy 1 )-1,2-dihydropyridin-3 -yl) oxy )benzonitrile used in the treatment HIV infection and AIDS.
